Double Medical Technology

Double Medical Technology ROCE

The Return on Capital Employed (ROCE) of Double Medical Technology (002901.SZ) as of Oct 16, 2026 is 19.51 %. In the previous year, Return on Capital Employed (ROCE) was 13.50 % — a change of 44.52% (higher).

ROCE

19.51 %

YoY

44.52%

Last updated:

In 2025, Double Medical Technology's return on capital employed (ROCE) was 19.51 %, a 44.52% increase from the 13.50 % ROCE in the previous year.

The Double Medical Technology ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
30.24 CNY
Jan 1, 2019
32.56 CNY
Jan 1, 2020
33.49 CNY
Jan 1, 2021
31.76 CNY
Jan 1, 2022
4.75 CNY
Jan 1, 2023
3.27 CNY
Jan 1, 2024
13.50 CNY
Jan 1, 2025
19.51 CNY
The Double Medical Technology ROCE history
YEARROCEYoY
19.51 %+44.52%
13.50 %+313.43%
3.27 %-31.20%
4.75 %-85.05%
31.76 %-5.18%
33.49 %+2.86%
32.56 %+7.70%
30.24 %+6.71%
28.33 %-32.37%
41.90 %-13.53%
48.46 %-16.74%
58.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Double Medical Technology Stock analysis

What does Double Medical Technology do? Double Medical Technology Inc, listed on the Shenzhen Stock Exchange under ticker 002901.SZ, operates in the Health Care sector with a focus on medical consumables. Headquartered in Xiamen, China, the company employs 3,793 full-time staff. It completed its initial public offering (IPO) on September 22, 2017. Double Medical Technology engages in the production, research and development, and sale of medical consumables, including orthopedic trauma implant materials, spinal implant materials, and nerve surgical implant materials. The company also manufactures surgical instruments. Its products are distributed both domestically within China and internationally. The firm's website is http://www.double-medical.com/. As a publicly traded entity, it provides medical products essential for surgical procedures and patient care, operating within the healthcare industry framework. The company's operations are centered around the development and supply of specialized medical devices and consumables, targeting healthcare providers and institutions globally. Double Medical Technology maintains a presence in both domestic and international markets, reflecting its strategic approach to market expansion and product distribution. Double Medical Technology is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Double Medical Technology's Return on Capital Employed (ROCE)

Double Medical Technology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Double Medical Technology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Double Medical Technology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Double Medical Technology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Double Medical Technology stock

Return on Capital Employed (ROCE) of Double Medical Technology is 19.51 % in 2025.

Return on Capital Employed (ROCE) of Double Medical Technology changed from 13.50 % to 19.51 %, representing a 44.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Double Medical Technology since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Double Medical Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Double Medical Technology

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Double Medical Technology